Publications en collaboration avec des chercheurs de Hospital Universitario 12 de Octubre (128)

2025

  1. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

    Blood Advances, Vol. 9, Núm. 3, pp. 571-582

  2. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

    American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

  3. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology

  4. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia

  5. Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132

2024

  1. 30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

    HemaSphere

  2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  3. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  4. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  5. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  6. Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients

    HemaSphere, Vol. 8, Núm. 12

  7. High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

    HemaSphere, Vol. 8, Núm. 12

  8. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology, Vol. 103, Núm. 12, pp. 5651-5661

  9. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood, Vol. 144, Núm. 23, pp. 2432-2438

  10. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  11. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  12. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

  13. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial

    Haematologica, Vol. 109, Núm. 12, pp. 4056-4066

  14. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347